Has Retatrutide plus Tirzepatide been studied in a clinical trial?

No. Both compounds have published trial records individually, but no clinical study has evaluated them in combination. Any claim about what the pairing does is extrapolation.

AMP-2P is a vendor product name applied to a two-peptide research blend in the incretin family. Sellers using it and comparable codes generally do not publish the composition, so the name identifies a catalogue item rather than a defined formulation. Treat the code as a search term, not a specification, and rely on an assay for identity.

Do Retatrutide and Tirzepatide target different receptors?

They overlap. Retatrutide is a triple GLP-1/GIP/glucagon agonist and tirzepatide is a dual GIP/GLP-1 agonist, so both act on GLP-1 and GIP. The only receptor arm not shared is glucagon, which retatrutide already provides alone.

Are these compounds banned under WADA rules for 2026?

GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited. WADA classification can change in future annual cycles, so verify against the current list.

PreppinPeppers › Facts › Lab article

Retatrutide + Tirzepatide: What the Pairing Actually Is

Machine-readable facts for this Lab article. The full page is https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide.

TL;DR

Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer combination. How the two reported receptor profiles overlap.

Facts Index

Fact ID	Category	Entity	Attribute	Value	Source
retatrutide-tirzepatide:title	identity	Retatrutide + Tirzepatide: What the Pairing Actually Is	title	Retatrutide + Tirzepatide: What the Pairing Actually Is	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:published	identity	Retatrutide + Tirzepatide: What the Pairing Actually Is	published	2026-08-18	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:author	identity	Retatrutide + Tirzepatide: What the Pairing Actually Is	author	Preppin' Peppers Editorial Team	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:topics	identity	Retatrutide + Tirzepatide: What the Pairing Actually Is	topics	research, stacks	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:summary	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	summary	Retatrutide plus Tirzepatide is a community- and vendor-named pairing, not a manufacturer combination. How the two reported receptor profiles overlap.	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-1	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	What it is	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-2	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	What it is	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-3	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	Why these are combined	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-4	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	What is not known	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-5	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	The components	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-6	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	Reconstitution and blending	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-7	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	Status in sport	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-8	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	Related reading	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:section-10	content	Retatrutide + Tirzepatide: What the Pairing Actually Is	section	What the research community gets wrong about Retatrutide + Tirzepatide	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-www-nejm-org	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity : A Phase 2 Trial. N Engl J Med, 2023 - www.nejm.org	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-pubchem-ncbi-nlm-nih-gov	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	NCBI PubChem CID 156588324: Tirzepatide (C225H348N48O68) - pubchem.ncbi.nlm.nih.gov	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-www-ncbi-nlm-nih-gov	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	Goldney et al., Curr Cardiovasc Risk Rep 2025: Triple Agonism Based Therapies for Obesity - www.ncbi.nlm.nih.gov	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-pmc-ncbi-nlm-nih-gov	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	Katsi et al., Biomolecules 2025: Retatrutide-A Game Changer in Obesity Pharmacotherapy - pmc.ncbi.nlm.nih.gov	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-pmc-ncbi-nlm-nih-gov-2	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	Nauck and D'Alessio, Cardiovasc Diabetol 2022: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - pmc.ncbi.nlm.nih.gov	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)
retatrutide-tirzepatide:source-pubmed-ncbi-nlm-nih-gov	source	Retatrutide + Tirzepatide: What the Pairing Actually Is	cites	Jastreboff et al., N Engl J Med 2022: Tirzepatide Once Weekly for the Treatment of Obesity - pubmed.ncbi.nlm.nih.gov	Lab article (https://www.preppinpeppers.com/blogs/the-lab/retatrutide-tirzepatide) (evidence)

FAQ

Has Retatrutide plus Tirzepatide been studied in a clinical trial?: No. Both compounds have published trial records individually, but no clinical study has evaluated them in combination. Any claim about what the pairing does is extrapolation.
What is AMP-2P?: AMP-2P is a vendor product name applied to a two-peptide research blend in the incretin family. Sellers using it and comparable codes generally do not publish the composition, so the name identifies a catalogue item rather than a defined formulation. Treat the code as a search term, not a specification, and rely on an assay for identity.
Do Retatrutide and Tirzepatide target different receptors?: They overlap. Retatrutide is a triple GLP-1/GIP/glucagon agonist and tirzepatide is a dual GIP/GLP-1 agonist, so both act on GLP-1 and GIP. The only receptor arm not shared is glucagon, which retatrutide already provides alone.
Are these compounds banned under WADA rules for 2026?: GLP-1 compounds appear on the 2026 WADA Monitoring Program — tracked but not currently prohibited. WADA classification can change in future annual cycles, so verify against the current list.